Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLR1023
- Development stage
- Phase 1
- Lead developer
- Gan & Lee Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
GLR1023 is a recombinant humanized monoclonal antibody developed by Gan & Lee Pharmaceuticals for the treatment of moderate-to-severe plaque psoriasis. It functions by specifically binding to and neutralizing interleukin-17A (IL-17A), a key pro-inflammatory cytokine involved in the development of psoriatic lesions. By inhibiting the interaction between IL-17A and its receptor, GLR1023 suppresses the inflammatory cascade and keratinocyte overproliferation characteristic of the disease. The drug is designed to provide a targeted therapeutic option for patients with autoimmune inflammatory conditions mediated by the IL-17 pathway.
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on GLR1023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLR1023.